ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions
View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM
Abstract Number: 2554
Changes in Blood Pressure Following the Initiation of Disease Modifying Therapies in US Veterans with Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events
9:00AM-11:00AM
Abstract Number: 2676
Changes in Salivary Gland Echostructure in Patients with Primary SjöGren’s Syndrome over the Time: A Four-Year Longitudinal Study
Sjögren's Syndrome - Poster II: Clinical Science
9:00AM-11:00AM
Abstract Number: 2850
Changes in Urinary Biomarker Levels Can Predict Treatment Responses in Lupus Nephritis
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis
9:00AM-11:00AM
Abstract Number: 2753
Characteristic and Outcomes of Psoriatic Arthritis Patients with Hyperuricemia, Whether We Should Treat or Not?
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III
9:00AM-11:00AM
Abstract Number: 2971
Characteristics and Management of IgA Vasculitis (Henoch-Schönlein purpura) in Adults: Data from the 260 Patients Included in the Igavas Survey
Vasculitis - Poster III: Rarer Vasculitides
9:00AM-11:00AM
Abstract Number: 2749
Characteristics of Ankylosing Spondylitis Patients with Primary and Secondary Lack of Efficacy to TNF-Inhibitor Treatments
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III
9:00AM-11:00AM
Abstract Number: 2688
Characteristics, Treatment and Outcome of Joint Involvement with Synovitis in Primary SjöGren’s Syndrome: French Multicentric Retrospective Case-Control Study
Sjögren's Syndrome - Poster II: Clinical Science
9:00AM-11:00AM
Abstract Number: 2431
Characterization of Innate Immune Cells in Patients with the Interferon-Mediated Autoinflammatory Diseases Sting Associated Vasculopathy with Onset in Infancy (SAVI) and Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature (CANDLE)
Pediatric Rheumatology – Pathogenesis and Genetics - Poster
9:00AM-11:00AM
Abstract Number: 2255
Characterization of Low-Density Granulocytes in Autoinflammatory Disorders
Innate Immunity and Rheumatic Disease - Poster II
9:00AM-11:00AM
Abstract Number: 2839
Circulating CD4+CD28null T-Cells Predict the Occurrence of New Lung Damage in  Systemic Lupus Erythematosus (SLE) Patients
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis
9:00AM-11:00AM
Abstract Number: 2681
Clinical and Immunological Characteristics of Primary Sjogren´s Syndrome in Men
Sjögren's Syndrome - Poster II: Clinical Science
9:00AM-11:00AM
Abstract Number: 2219
Clinical and Radiological Characteristics of Patients with Adhesive Capsulitis and Shoulder Impingement Syndrome
Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster II: Clinical Focus
9:00AM-11:00AM
Abstract Number: 2400
Clinical and Treatment Factors Associated with Antibiotic-Refractory Lyme Arthritis in Children
Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous
9:00AM-11:00AM
Abstract Number: 2934
Clinical Assessment of the Monoclonal Anitbody, PRX003, a Potential Novel Treatment for Th17-Mediated Inflammatory Disease
T Cell Biology and Targets in Autoimmune Disease - Poster Session II
9:00AM-11:00AM
Abstract Number: 2388
Clinical Characterization and Outcomes of Pediatric Chronic Nonbacterial Osteomyelitis
Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous
  • «Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 69
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology